Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations

Royal Devon and Exeter NHS Foundation Trust50 enrolled

Overview

The purpose of this study is to investigate whether patients with diabetes due to Kir6.2 mutations can be treated with sulfonylurea medication rather than insulin, and if this is the case to investigate the mechanism for sulfonylurea response.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus

Interventions

SulfonylureaDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetes due to KCNJ11 (Kir6.2) mutation Exclusion Criteria: * None

Outcomes

Primary Outcomes

HbA1c reduction

Secondary Outcomes

insulin secretory response to intravenous glucose

insulin secretory response to oral glucose

insulin secretory response to mixed meal (sustacal)

Incidence of Hypoglycemia

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.